EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole

Area of Science:

• Medical Microbiology
• Clinical Pharmacology
• Infectious Diseases

Background:

• Antifungal susceptibility testing is crucial for guiding therapy against Candida infections.
• Established breakpoints help interpret the clinical significance of in vitro susceptibility results.
• Previous breakpoints may not fully reflect the efficacy of certain antifungal agents against specific Candida species.

Purpose of the Study:

• To present the rationale behind newly determined and revised antifungal susceptibility testing breakpoints.
• To provide updated guidance for micafungin, anidulafungin, and fluconazole against Candida species.
• To inform clinical decisions regarding antifungal drug selection and dosing.

Main Methods:

• Determination of micafungin breakpoints based on pharmacokinetic (PK) data, animal PK/pharmacodynamic (PD) data, microbiological data, and clinical experience.
• Revision of anidulafungin and fluconazole breakpoints to species-specific values.
• Categorization of wild-type strains as intermediate for specific species to accommodate clinical use.

Main Results:

• New breakpoints for micafungin against Candida species have been established.
• Revised, species-specific breakpoints for anidulafungin (against C. parapsilosis) and fluconazole (against C. glabrata) were determined.
• These revised breakpoints categorize wild-type isolates as intermediate, supporting specific clinical applications.

Conclusions:

• The updated breakpoints provide a refined framework for interpreting antifungal susceptibility testing results.
• Species-specific adjustments for anidulafungin and fluconazole enhance the clinical utility of susceptibility data.
• These changes support optimized antifungal treatment strategies for invasive Candida infections.